[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023011814A - Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer. - Google Patents

Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.

Info

Publication number
MX2023011814A
MX2023011814A MX2023011814A MX2023011814A MX2023011814A MX 2023011814 A MX2023011814 A MX 2023011814A MX 2023011814 A MX2023011814 A MX 2023011814A MX 2023011814 A MX2023011814 A MX 2023011814A MX 2023011814 A MX2023011814 A MX 2023011814A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
cancer
amelioration
treatment
compounds
Prior art date
Application number
MX2023011814A
Other languages
English (en)
Inventor
Thomas Bohnacker
Martin Schwill
Stefanie Flückiger-Mangual
Dorothea Gruber
Debora Schmitz-Rohmer
Charles- Henry Fabritius
Koen Hekking
Rutger Folmer
Original Assignee
Tolremo Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolremo Therapeutics Ag filed Critical Tolremo Therapeutics Ag
Publication of MX2023011814A publication Critical patent/MX2023011814A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) o sales, solvatos, cocristales, tautómeros o mezclas de los mismos. Además, la presente invención se refiere a composiciones farmacéuticas que comprenden dichos compuestos. Además, la presente invención se refiere a los compuestos de la fórmula (I) o a las sales, solvatos, cocristales, tautómeros, o mezclas de los mismos o a las composiciones farmacéuticas para su uso como medicamento y a los compuestos de la fórmula (I) o a las sales, solvatos, cocristales, tautómeros, o mezclas de los mismos o a las composiciones farmacéuticas para su uso en el tratamiento o mejora del cáncer. Opcionalmente, los compuestos de la fórmula (I) o las sales, solvatos, cocristales, tautómeros o mezclas de los mismos o las composiciones farmacéuticas se administran en combinación con un segundo agente terapéutico, en particular un agente anticancerígeno.
MX2023011814A 2021-04-07 2022-04-07 Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer. MX2023011814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21167278 2021-04-07
PCT/EP2022/059295 WO2022214606A1 (en) 2021-04-07 2022-04-07 Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer

Publications (1)

Publication Number Publication Date
MX2023011814A true MX2023011814A (es) 2023-10-13

Family

ID=75426525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011814A MX2023011814A (es) 2021-04-07 2022-04-07 Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.

Country Status (13)

Country Link
US (1) US20240327394A1 (es)
EP (1) EP4320109A1 (es)
JP (1) JP2024515061A (es)
KR (1) KR20230167092A (es)
CN (1) CN117355512A (es)
AR (1) AR125312A1 (es)
AU (1) AU2022253869A1 (es)
BR (1) BR112023020538A2 (es)
CA (1) CA3212085A1 (es)
IL (1) IL307402A (es)
MX (1) MX2023011814A (es)
TW (1) TW202304882A (es)
WO (1) WO2022214606A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7379355B2 (ja) * 2017-11-20 2023-11-14 トルレモ セラピューティクス アーゲー 診断方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ES2195408T5 (es) 1997-09-29 2010-11-25 Novartis Ag Procedimiento de formación de polvo que comprende micropartículas perforadas.
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
IT201700047189A1 (it) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
JP7395723B2 (ja) * 2019-10-02 2023-12-11 トルレモ・セラピューティクス・アクチェンゲゼルシャフト 複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
EP4320109A1 (en) 2024-02-14
TW202304882A (zh) 2023-02-01
JP2024515061A (ja) 2024-04-04
IL307402A (en) 2023-12-01
US20240327394A1 (en) 2024-10-03
AR125312A1 (es) 2023-07-05
CN117355512A (zh) 2024-01-05
WO2022214606A1 (en) 2022-10-13
BR112023020538A2 (pt) 2024-01-23
KR20230167092A (ko) 2023-12-07
AU2022253869A1 (en) 2023-10-05
CA3212085A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
KR100938712B1 (ko) 히스톤 데아세틸라제 저해 물질을 함유하는 의약 조성물
CR20230286A (es) Inhibidores de prmt5 novedosos
SA520420033B1 (ar) مركبات صيدلية
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20170157134A1 (en) Combination therapy
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2023011814A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.
MX2023001823A (es) Terapia de combinacion.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
BR112014016632A8 (pt) uso terapêutico de derivados de imidazopiridina
ZA202206436B (en) Macrocyclic pantetheine derivatives and uses thereof
MX2024000239A (es) Medicamentos que comprenden inhibidores de la glicosidasa.
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.